{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-045300","form_type":"8-K","ticker":"RNAZ","cik":"0001829635","company_name":"Transcode Therapeutics, Inc.","filed_at":"2023-04-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.957690+00:00","generated_at":"2026-06-17T02:07:23.979975+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"TransCode enters $1.08M equity line with White Lion Capital for TTX-MC138 development","bullets":["Up to $1.08M in common stock purchase agreement with White Lion Capital; proceeds for working capital and TTX-MC138 development.","Purchase price set at 92% of lower of 2-day VWAP or lowest closing price during valuation period.","Commitment period ends May 31, 2023; if less than 1.5M shares sold by then, company must deliver shares to White Lion.","Exchange cap of 3,163,124 shares (19.99% of outstanding) unless average price >= $0.39 or stockholder approval.","Shares offered under effective shelf registration statement (File No. 333-268764)."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-045300","json":"https://secwatch.observer/filing/0001104659-23-045300.json","markdown":"https://secwatch.observer/filing/0001104659-23-045300.md","text":"https://secwatch.observer/filing/0001104659-23-045300.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1829635/000110465923045300/0001104659-23-045300-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1829635/000110465923045300/tm2312650d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T02:07:23.979975+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2772781ca5487dff7c7bc20e7724751e4afe5128","claim":"Transcode Therapeutics, Inc. entered into White Lion Purchase Agreement with White Lion Capital, LLC valued at up to $1,081,307 (effective 2023-04-13).","evidence_excerpt":"On April 13, 2023, TransCode Therapeutics, Inc. (the “Company”) entered into a Common Stock Purchase Agreement (the “White Lion Purchase Agreement”) with White Lion Capital, LLC, a Nevada limited liability company (“White Lion”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1829635/000110465923045300/0001104659-23-045300-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"White Lion Capital, LLC"},{"label":"Value","value":"up to $1,081,307"},{"label":"Effective","value":"2023-04-13"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}